Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Jereb Berta) .

1 - 10 / 49
Na začetekNa prejšnjo stran12345Na naslednjo stranNa konec
1.
2.
Gonadal function in patients treated for Hodgkin's disease in childhood
Lorna Zadravec-Zaletel, Nevenka Bratanič, Berta Jereb, 2010, izvirni znanstveni članek

Objavljeno v DiRROS: 15.03.2024; Ogledov: 54; Prenosov: 23
.pdf Celotno besedilo (652,65 KB)

3.
Choroid plexus carcinoma : a case report
Primož Strojan, Mara Popović, Katarina Šurlan Popović, Berta Jereb, 2004, kratki znanstveni prispevek

Objavljeno v DiRROS: 13.02.2024; Ogledov: 109; Prenosov: 23
.pdf Celotno besedilo (179,15 KB)

4.
Evolving strategies in the treatment of childhood rhabdomyosarcoma : Slovenian experience
Živa Pohar-Marinšek, Jožica Anžič, Berta Jereb, 2001, izvirni znanstveni članek

Povzetek: Background. Neoadjuvant chemotherapy (Cht) has changed the treatment of rhabdomyosarcoma (RMS) in children. The purpose of our study was to review thechildren treated for RMS between 1974 and 1996. Patients and methods. Fifty-one children, 1-15 years old, were included. Primary sites of tumour were: head and neck 15, orbit 6, genitourinary 12, extremity 9, torso 5 and paratesticular 4. Twelve patients were in stage 1, 10 in stage II, 26 in stage111 and 3 in stage IV. Of 43 histologically confirmed RMS 25 were embryonal, 13 alveolar, 1 botryoid, 1 spindle cell and 3 sarcoma NOS. In 8 patients, only fine needle aspiration biopsy (FNAB) was available. All patients had Cht, 29 neoadjuvant, 20 had surgery first, 40 had irradiation (RT), 2 stage IV patients had bone marrow transplant (ABMT). Multidrug Cht varied: VCR, AMD, and cyclophosphamide (VAC) were used in the 1970s, with Adriablastine (T2), methotrexat (MTX) and/or other drugs (T6, T11) in the 1980s; and in the 1990s, cyclophosphamide was replaced by ifosfamide (VAIA). The treatment was started with Cht in orbital and head and neck tumours and inthe majority of genitourinary tumours, but surgery was first in paratesticular and in the majority of extremity tumours. Results. The 3 patients with stage IV disease died. Of those with localised tumour, 34 (70%) were alive and well 5 years after treatment, 80% stage I, 75% stage II and 61%stage III. One patient died of heart failure, 3 of Cht toxicity and 1 of intereurrent disease. Conclusions. (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 26.01.2024; Ogledov: 124; Prenosov: 28
.pdf Celotno besedilo (177,30 KB)

5.
Interferon alpha (IFN-[alpha]) in treatment of malignant diseases
Berta Jereb, 1997, pregledni znanstveni članek

Povzetek: There are several natural varieties of IFN-alpha in clinical use. Although IFNs were the first cytokines in use as a new treatment modality, we still know little about their mode of action in malignancies. IFN-alpha can inhibit cell growth, but it has been shown only recently, on malignant cells from patients with multiple myeloma, that IFN-alpha can exert a direct cytotoxic effect on tumor cells. The treatment with natural leucocyte IFN-alpha in dosesused in the early clinical trials, are still most widely used. It has been shown that through a high local concentration by local application in malignant melanoma, basalioma, pleural carcinosis, glioblastoma, total local tumor control may be achieved. it is thys not known what the optimal doses of IFN-alpha are, and they may vary by the tumor type, as well as from patient topatient. The neccessary duration of treatment also remains an open question.IFNs are a tool for treatment of malignant tumors. Their cytotoxic effect, however, is not strong enough and does not last. At present, there is a vast field of investigative work stil open-but in the meantime it seems necessary to proceed with clinical trials of different types of IFN, the natural IFN-alpha again beeing the most interesting one.
Objavljeno v DiRROS: 18.01.2024; Ogledov: 124; Prenosov: 23
.pdf Celotno besedilo (374,38 KB)

6.
7.
Radiation toxicity - bone marrow and leukemia
Berta Jereb, 1996, objavljeni povzetek znanstvenega prispevka na konferenci

Objavljeno v DiRROS: 16.01.2024; Ogledov: 122; Prenosov: 35
.pdf Celotno besedilo (51,28 KB)

8.
Risk for recurrence of intracranial germinoma
Primož Strojan, Mara Popović, Gabrijela Petrič-Grabnar, Nežika Župančič, Berta Jereb, 1996, izvirni znanstveni članek

Objavljeno v DiRROS: 16.01.2024; Ogledov: 126; Prenosov: 39
.pdf Celotno besedilo (626,83 KB)

9.
10.
Iskanje izvedeno v 0.2 sek.
Na vrh